Week Ending October 10, 2022

Lung Cancer Gene Signatures May Predict Response to Chemotherapy
“Researchers at the Francis Crick Institute have developed a method that could help predict whether people with lung cancer will respond to chemotherapy, based on which genes are switched on in their tumor.”

Lung Cancer Space Must ‘Maximize’ the People Who Benefit From Advancements
“Lung cancer advocates and clinicians must ”fight” for every patient with the disease and ensure that the most amount of people can benefit from advancements in the field, according to an advocate.”

An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations 
“Mutations in oncogenes such as KRAS and EGFR cause a high proportion of lung cancers. Drugs targeting these proteins cause tumor regression but ultimately fail to elicit cures. As a result, there is an intense interest in how to best combine targeted therapies with other treatments, such as immunotherapies.”

Lung Cancer in Nonsmokers? Study Identifies Air Pollution as a Trigger
“For weeks, Molly Campbell had an intermittent dry, hacking cough that she could not shake. After a pair of doctor visits, she was prescribed steroids and an inhaler. Nothing worked. Then, about three months in, she started coughing up blood.”

Sapanisertib Receives Fast Track Designation by the FDA for Advanced NSCLC
“Fast track designation was granted to sapanisertib by the FDA for patients with unresectable or metastatic squamous cell non–small cell lung cancer who have an NRF2 mutation.”

Dostarlimab Plus Chemotherapy Shows Promise in Non-Small Cell Lung Cancer
“Results from the largest head-to-head trial of programmed death receptor-1 inhibitors suggest that dostarlimab and chemotherapy could be an effective treatment option for patients with metastatic non-squamous non-small cell lung cancer.”

Multi-Chemotherapy Regimen Elicits Improved Outcomes in Rare Form of Pediatric Lung Cancer, But More Research is Needed
“The use of a multi-agent chemotherapy regimen resulted in improved outcomes in a group of children with pleuropulmonary blastoma, a rare form of lung cancer, when compared with other regimens.”

The Anticancer Potential of Chlorine Dioxide in Small-Cell Lung Cancer Cells
“Chlorine dioxide (ClO2) is an effective disinfectant consisting of oxygen, chloride, and potassium. Because of its high oxidative capacity, ClO2 exerts antimicrobial, antiviral, and antifungal effects. However, its anticancer effects remain to be elucidated.”

Roundtable Discussion: Neal Discusses Molecular Testing and Treatment for EGFR Exon 20+ Lung Cancer
“During a case-based roundtable event, Joel W. Neal, MD, PhD of Stanford Cancer Institute and a group of peers discussed using molecular testing to detect an EGFR exon 20 insertion in a patient with lung cancer.”

Treatment Decisions in Non-Small Cell Lung Cancer
“In a recent OncLive® Scientific Interchange, Roy S. Herbst, MD, PhD served as the moderator for a discussion on n using immunotherapy (IO) and targeted therapeutics in patients with NSCLC, to discuss factors impacting therapeutic selection and sequencing strategies in NSCLC, and to evaluate and obtain feedback on the evolving landscape of immunotherapy–based regimens in treating the disease.”

The Price of Being Invisible: How One Black Woman Fought for Her Lung Cancer Diagnosis
“Nichelle Stigger knew she had cancer. Her doctors didn’t believe her — for a full six months. She says the fact that she is a Black American, and a woman, has everything to do with it. Now a five-year lung cancer survivor, the 40-year-old mother, wife, and teacher is an activist who freely shares her experiences and hard-won wisdom to help others deal with the medical establishment.”

Benefit of Immunotherapy in SCLC Remains a Question
“Gene G. Finley, MD, medical oncologists at Allegheny Clinic Medical Oncology of Allegheny Health Network, explains a questions lingering on the benefit of immunotherapy in patients with small call lung cancer.”